Anti-p53 TCR-Gene Engineered Lymphocytes
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-p53 TCR-Gene Engineered Lymphocytes, covering 2011-08-05 to 2011-08-05. Get the full timeline:
Most recent: Clinical Trial Update: Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes [Phase 2]